Hodgkin's lymphoma in systemic lupus erythematosus

Sasha Bernatsky, R. Ramsey-Goldman, D. Isenberg, A. Rahman, M. A. Dooley, J. Sibley, J. F. Boivin, L. Joseph, James Olen Armitage, A. Zoma, A. Clarke

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective. In systemic lupus erythematosus (SLE), there is a well-documented increased risk of non-Hodgkin's lymphoma (NHL), but little is known about the risk of Hodgkin's lymphoma (HL). The purpose of our work was to describe the phenomenon of HL in SLE. Methods. A multi-site cohort of 9547 SLE subjects was assembled; HL cases were ascertained through cancer registry linkage, and the standardized incidence ratio (SIR) for HL was determined. We also performed a literature search for HL cases in SLE, and compared these with our sample. Finally, we pooled results from our cohort study with two large population-based cohort studies providing SIR estimates for HL in SLE. Results. Five cases of HL occurred in our SLE cohort during the observation interval, for an SIR of 2.4 (95% CI 0.8, 5.5). The literature review documented 13 HL case reports developing in patients with SLE. A pooled analysis combining our data with the other large cohort studies yielded a standardized incidence ratio of 3.16 (95% CI, 1.63-5.51) for HL in SLE. Conclusions. Data suggest that risk in SLE is increased not only for NHL, but also for other malignancies arising from B-lymphocytes, including HL.

Original languageEnglish (US)
Pages (from-to)830-832
Number of pages3
JournalRheumatology
Volume46
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Hodgkin Disease
Systemic Lupus Erythematosus
Cohort Studies
Incidence
Non-Hodgkin's Lymphoma
Registries
Neoplasms
B-Lymphocytes
Observation

Keywords

  • Hodgkin's lymphoma
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Bernatsky, S., Ramsey-Goldman, R., Isenberg, D., Rahman, A., Dooley, M. A., Sibley, J., ... Clarke, A. (2007). Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology, 46(5), 830-832. https://doi.org/10.1093/rheumatology/kel444

Hodgkin's lymphoma in systemic lupus erythematosus. / Bernatsky, Sasha; Ramsey-Goldman, R.; Isenberg, D.; Rahman, A.; Dooley, M. A.; Sibley, J.; Boivin, J. F.; Joseph, L.; Armitage, James Olen; Zoma, A.; Clarke, A.

In: Rheumatology, Vol. 46, No. 5, 01.05.2007, p. 830-832.

Research output: Contribution to journalArticle

Bernatsky, S, Ramsey-Goldman, R, Isenberg, D, Rahman, A, Dooley, MA, Sibley, J, Boivin, JF, Joseph, L, Armitage, JO, Zoma, A & Clarke, A 2007, 'Hodgkin's lymphoma in systemic lupus erythematosus', Rheumatology, vol. 46, no. 5, pp. 830-832. https://doi.org/10.1093/rheumatology/kel444
Bernatsky S, Ramsey-Goldman R, Isenberg D, Rahman A, Dooley MA, Sibley J et al. Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology. 2007 May 1;46(5):830-832. https://doi.org/10.1093/rheumatology/kel444
Bernatsky, Sasha ; Ramsey-Goldman, R. ; Isenberg, D. ; Rahman, A. ; Dooley, M. A. ; Sibley, J. ; Boivin, J. F. ; Joseph, L. ; Armitage, James Olen ; Zoma, A. ; Clarke, A. / Hodgkin's lymphoma in systemic lupus erythematosus. In: Rheumatology. 2007 ; Vol. 46, No. 5. pp. 830-832.
@article{58d8b7fadac44733a1b447ee38e94b8f,
title = "Hodgkin's lymphoma in systemic lupus erythematosus",
abstract = "Objective. In systemic lupus erythematosus (SLE), there is a well-documented increased risk of non-Hodgkin's lymphoma (NHL), but little is known about the risk of Hodgkin's lymphoma (HL). The purpose of our work was to describe the phenomenon of HL in SLE. Methods. A multi-site cohort of 9547 SLE subjects was assembled; HL cases were ascertained through cancer registry linkage, and the standardized incidence ratio (SIR) for HL was determined. We also performed a literature search for HL cases in SLE, and compared these with our sample. Finally, we pooled results from our cohort study with two large population-based cohort studies providing SIR estimates for HL in SLE. Results. Five cases of HL occurred in our SLE cohort during the observation interval, for an SIR of 2.4 (95{\%} CI 0.8, 5.5). The literature review documented 13 HL case reports developing in patients with SLE. A pooled analysis combining our data with the other large cohort studies yielded a standardized incidence ratio of 3.16 (95{\%} CI, 1.63-5.51) for HL in SLE. Conclusions. Data suggest that risk in SLE is increased not only for NHL, but also for other malignancies arising from B-lymphocytes, including HL.",
keywords = "Hodgkin's lymphoma, Systemic lupus erythematosus",
author = "Sasha Bernatsky and R. Ramsey-Goldman and D. Isenberg and A. Rahman and Dooley, {M. A.} and J. Sibley and Boivin, {J. F.} and L. Joseph and Armitage, {James Olen} and A. Zoma and A. Clarke",
year = "2007",
month = "5",
day = "1",
doi = "10.1093/rheumatology/kel444",
language = "English (US)",
volume = "46",
pages = "830--832",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Hodgkin's lymphoma in systemic lupus erythematosus

AU - Bernatsky, Sasha

AU - Ramsey-Goldman, R.

AU - Isenberg, D.

AU - Rahman, A.

AU - Dooley, M. A.

AU - Sibley, J.

AU - Boivin, J. F.

AU - Joseph, L.

AU - Armitage, James Olen

AU - Zoma, A.

AU - Clarke, A.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Objective. In systemic lupus erythematosus (SLE), there is a well-documented increased risk of non-Hodgkin's lymphoma (NHL), but little is known about the risk of Hodgkin's lymphoma (HL). The purpose of our work was to describe the phenomenon of HL in SLE. Methods. A multi-site cohort of 9547 SLE subjects was assembled; HL cases were ascertained through cancer registry linkage, and the standardized incidence ratio (SIR) for HL was determined. We also performed a literature search for HL cases in SLE, and compared these with our sample. Finally, we pooled results from our cohort study with two large population-based cohort studies providing SIR estimates for HL in SLE. Results. Five cases of HL occurred in our SLE cohort during the observation interval, for an SIR of 2.4 (95% CI 0.8, 5.5). The literature review documented 13 HL case reports developing in patients with SLE. A pooled analysis combining our data with the other large cohort studies yielded a standardized incidence ratio of 3.16 (95% CI, 1.63-5.51) for HL in SLE. Conclusions. Data suggest that risk in SLE is increased not only for NHL, but also for other malignancies arising from B-lymphocytes, including HL.

AB - Objective. In systemic lupus erythematosus (SLE), there is a well-documented increased risk of non-Hodgkin's lymphoma (NHL), but little is known about the risk of Hodgkin's lymphoma (HL). The purpose of our work was to describe the phenomenon of HL in SLE. Methods. A multi-site cohort of 9547 SLE subjects was assembled; HL cases were ascertained through cancer registry linkage, and the standardized incidence ratio (SIR) for HL was determined. We also performed a literature search for HL cases in SLE, and compared these with our sample. Finally, we pooled results from our cohort study with two large population-based cohort studies providing SIR estimates for HL in SLE. Results. Five cases of HL occurred in our SLE cohort during the observation interval, for an SIR of 2.4 (95% CI 0.8, 5.5). The literature review documented 13 HL case reports developing in patients with SLE. A pooled analysis combining our data with the other large cohort studies yielded a standardized incidence ratio of 3.16 (95% CI, 1.63-5.51) for HL in SLE. Conclusions. Data suggest that risk in SLE is increased not only for NHL, but also for other malignancies arising from B-lymphocytes, including HL.

KW - Hodgkin's lymphoma

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=34347259291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347259291&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kel444

DO - 10.1093/rheumatology/kel444

M3 - Article

C2 - 17255135

AN - SCOPUS:34347259291

VL - 46

SP - 830

EP - 832

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 5

ER -